Search results

597 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Public health guidelines Remove Public health guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter

Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]

In development [GID-TA10498] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Cenobamate for focal onset seizures in epilepsy [ID1553]

In development [GID-TA10661] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

In development [GID-TA10606] Expected publication date: 08 June 2022

Type

Technology appraisal guidance

Status

In development
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]

In development [GID-TA10630] Expected publication date: 23 March 2022

Type

Technology appraisal guidance

Status

In development
Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm [ID1556]

In development [GID-TA10482] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

In development [GID-TA10513] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]

In development [GID-TA10650] Expected publication date: 25 August 2021

Type

Technology appraisal guidance

Status

In development
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

In development [GID-TA10612] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]

In development [GID-TA10619] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]

In development [GID-TA10624] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488

In development [GID-TA10432] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

In development [GID-TA10470] Expected publication date: 27 January 2021

Type

Technology appraisal guidance

Status

In development
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]

In development [GID-TA10626] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1647]

In development [GID-TA10703] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]

In development [GID-TA10381] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Workplace health - older employees

In development [GID-PHG59] Expected publication date: 24 March 2016

Type

NICE guideline

Status

In development
Personal, social, health and economic education focusing on sex and relationships and alcohol education

In development [GID-PHG0] Expected publication date: TBC

Type

NICE guideline

Status

In development
Housing: planning to improve health and wellbeing

In development [GID-NG10053] Expected publication date: TBC

Type

NICE guideline

Status

In development
Workplace health for employees with disabilities and long-term conditions

In development [GID-PHG58] Expected publication date: TBC

Type

NICE guideline

Status

In development
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

In development [GID-DT9] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care

In development [GID-DT28] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

In development [GID-IP1151] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Extra corporeal membrane oxygenation for acute heart failure in children

In development [GID-IP1153] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Degradable surgical implant

In development [GID-IP1197] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
MRI guided focussed ultrasound for chronic pain

In development [GID-IP1043] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Ex utero intrapartum therapy for fetal obstruction

In development [GID-IP1156] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Peroral endoscopic myotomy (POEM) for achalasia

In development [GID-IP1229] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

In development [GID-IP1170] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Intravaginal sling for stress urinary incontinence

In development [GID-IP267] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Electrochemotherapy for the treatment of malignant melanoma

In development [GID-IP1041] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Cutting blocks for total knee arthroplasty

In development [GID-IP1112] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Implantable Vagus Nerve Stimulator in Heart Failure

In development [GID-IP1145] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

In development [GID-TA10254] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Luspatercept for treating beta-thalassaemia ID1554

In development [GID-TA10506] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Kidney transplantation (rejection) - everolimus [ID117]

In development [GID-TAG241] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Eltrombopag for untreated severe aplastic anaemia ID1198

In development [GID-TA10284] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with epacadostat for untreated malignant melanoma ID1423

In development [GID-TA10330] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228

In development [GID-TA10203] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]

In development [GID-TA10149] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bevacizumab for untreated malignant pleural mesothelioma (ID1183)

In development [GID-TA10197] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

In development [GID-TAG321] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]

In development [GID-TAG482] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250

In development [GID-TA10213] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

In development [GID-TAG507] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development